Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Fatal Renal Bleeding in a Patient Treated With Aggressive Antithrombotic Therapy After Recurrent Coronary Stent Thrombosis

  • Moon, Jeong-Geun (Cardiology Division, Department of Internal Medicine, Severance Cardiovascular Hospital) ;
  • Lee, Sang-Hak (Cardiology Division, Department of Internal Medicine, Severance Cardiovascular Hospital) ;
  • Yang, Woo-In (Cardiology Division, Department of Internal Medicine, Severance Cardiovascular Hospital) ;
  • Ko, Young-Guk (Cardiology Division, Department of Internal Medicine, Severance Cardiovascular Hospital) ;
  • Han, Woong-Kyu (Department of Urology, Yonsei University College of Medicine) ;
  • Jang, Yang-Soo (Cardiology Division, Department of Internal Medicine, Severance Cardiovascular Hospital)
  • Received : 2010.02.18
  • Accepted : 2010.04.05
  • Published : 2010.07.30
⟨ Previous Next ⟩

Abstract

Triple antiplatelet therapy has been known to be superior to the conventional dual regimen for preventing stent thrombosis after coronary stenting, and the addition of oral anticoagulation to antiplatelet therapy is also considered an option. However, the risks and benefits of a triple antiplatelet regimen plus additional oral anticoagulation must be taken into account. Here, we report a case of fatal renal bleeding in a patient treated with triple antiplatelet plus oral anticoagulant therapy for the prevention of recurrent stent thrombosis.

Keywords

References

  1. Honda Y, Fitzgerald PJ. Stent thrombosis: an issue revisited in a changing world. Circulation 2003;108:2-5. https://doi.org/10.1161/01.CIR.0000075929.79964.D8
  2. Gurbel PA, DiChiara J, Tantry US. Antiplatelet therapy after implantation of drug-eluting stents: duration, resistance, alternatives, and management of surgical patients. Am J Cardiol 2007;100:18M-25M.
  3. Jaffe R, Strauss BH. Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives. J Am Coll Cardiol 2007;50: 119-27. https://doi.org/10.1016/j.jacc.2007.04.031
  4. Manzano-Fernandez S, Marin F, Pastor-Perez FJ, et al. Impact of chronic kidney disease on major bleeding complications and mortality in patients with indication for oral anticoagulation undergoing coronary stenting. Chest 2009;135:983-90. https://doi.org/10.1378/chest.08-1425
  5. Manzano-Fernandez S, Pastor FJ, Marin F, et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest 2008;134:559-67. https://doi.org/10.1378/chest.08-0350
  6. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL- RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009;53:1101-9. https://doi.org/10.1016/j.jacc.2008.12.025
  7. Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009;157:733-9. https://doi.org/10.1016/j.ahj.2009.01.006
  8. Lee SW, Park SW, Kim YH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 2008;51:1181-7. https://doi.org/10.1016/j.jacc.2007.11.049
  9. Lee SW, Park SW, Kim YH, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE- Long trial). Am J Cardiol 2007;100:1103-8. https://doi.org/10.1016/j.amjcard.2007.05.032
  10. Jeon DS, Yoo KD, Park CS, et al. The effect of cilostazol on stent thrombosis after drug-eluting stent implantation. Korean Circ J 2010; 40:10-5. https://doi.org/10.4070/kcj.2010.40.1.10
  11. Yang TH, Kim DI, Kim JY, et al. Comparison of triple anti-platelet therapy (aspirin, clopidogrel, and cilostazol) and double anti-platelet therapy (aspirin and clopidogrel) on platelet aggregation in type 2 diabetic patients undergoing drug-eluting stent implantation. Korean Circ J 2009;39:462-6. https://doi.org/10.4070/kcj.2009.39.11.462
  12. Francescone S, Halperin JL. "Triple therapy" or triple threat?: balancing the risks of antithrombotic therapy for patients with atrial fibrillation and coronary stents. J Am Coll Cardiol 2008;51:826-7. https://doi.org/10.1016/j.jacc.2007.11.034
  13. Rossini R, Musumeci G, Lettieri C, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol 2008;102:1618-23. https://doi.org/10.1016/j.amjcard.2008.08.021
  14. Ruiz-Nodar JM, Marin F, Hurtado JA, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008;51: 818-25. https://doi.org/10.1016/j.jacc.2007.11.035
  15. Lip GY, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest 2006;130:1823-7. https://doi.org/10.1378/chest.130.6.1823
  16. Grantham JJ. Clinical practice: autosomal dominant polycystic kidney disease. N Engl J Med 2008;359:1477-85. https://doi.org/10.1056/NEJMcp0804458

Cited by

  1. The Effect of FLT1 Variant on Long-Term Cardiovascular Outcomes: Validation of a Locus Identified in a Previous Genome-Wide Association Study vol.11, pp.10, 2010, https://doi.org/10.1371/journal.pone.0164705